PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18260357-8 2008 The histological diagnosis was PSS, and the patient received VIP (etoposide, ifosfamide, cisplatin) chemotherapy regimen. Etoposide 66-75 vasoactive intestinal peptide Homo sapiens 61-64 19302957-9 2009 One patient treated with maxillectomy, postoperative radiotherapy, and 5 courses of VIP chemotherapy (cisplatinum, etoposide, ifosfomide) died with brain metastases 10 months after diagnosis. Etoposide 115-124 vasoactive intestinal peptide Homo sapiens 84-87 18260360-8 2008 Then he was given one more cycle of VIP therapy (etoposide, ifosfamide, cisplatin), but the serum AFP level was increased to 56 ng/ml. Etoposide 49-58 vasoactive intestinal peptide Homo sapiens 36-39 17189930-7 2006 After surgery, the patient received 5 cycles of adjuvant chemotherapy with VIP (etoposide, ifosfamide, and cisplatin) regimen. Etoposide 80-89 vasoactive intestinal peptide Homo sapiens 75-78 18079577-4 2007 Among the most used ones, BEP and VIP (etoposide, cisplatin, and ifosfamide) have been the most studied. Etoposide 39-48 vasoactive intestinal peptide Homo sapiens 34-37 15596925-0 2004 VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors. Etoposide 5-14 vasoactive intestinal peptide Homo sapiens 0-3 16508731-9 2006 An additional three courses of BEP and five courses of VIP (cisplatin, ifosfamide, etoposide) normalized the beta-hCG level. Etoposide 83-92 vasoactive intestinal peptide Homo sapiens 55-58 12673712-3 2003 This study updated the intergroup trial that compared the standard therapy of bleomycin, etoposide, and cisplatin (BEP) with etoposide, ifosfamide, and cisplatin (VIP) in advanced germ cell tumors and reanalyzed the results using the IGCCCG staging system. Etoposide 125-134 vasoactive intestinal peptide Homo sapiens 163-166 11210163-3 2000 We conducted a phase II study of etoposide (VP-16)-ifosfamide-cisplatin (VIP) combination chemotherapy plus early concurrent thoracic irradiation for the patients with previously untreated limited small cell lung cancer in order to assess if the treatment modality could improve the response rate and the toxicity. Etoposide 33-42 vasoactive intestinal peptide Homo sapiens 73-76 11391579-2 2001 The purpose of this trial was to evaluate the response rate, progression free survival, overall survival, and toxicity of combined etoposide, ifosfamide, and cisplatin (VIP) in patients with advanced thymoma and thymic carcinoma. Etoposide 131-140 vasoactive intestinal peptide Homo sapiens 169-172 10723177-0 2000 [Treatment results of VIP (etoposide, ifosfamide and cisplatin) chemotherapy as a first-line therapy in metastatic germ cell tumors]. Etoposide 27-36 vasoactive intestinal peptide Homo sapiens 22-25 10897015-6 2000 In view of these findings, the authors treated STS patients with an etoposide, cisplatin, and ifosfamide (VIP) combination. Etoposide 68-77 vasoactive intestinal peptide Homo sapiens 106-109 10723177-2 2000 PATIENTS AND METHODS: From March 1994 to October 1997, we treated 16 patients with VIP therapy consisting of etoposide (100 mg/m2), ifosfamide, (1.2 g/m2) and cisplatin (20 mg/m2), all of which were generally given daily for 5 consecutive days every 3 weeks. Etoposide 109-118 vasoactive intestinal peptide Homo sapiens 83-86 10422441-6 1999 Following the right high orchiectomy, 4 cycles of VIP chemotherapy consisting of ifosfamide, etoposide and cisplatin were given, which resulted in partial response of the retroperitoneal mass and complete regression of the supraculavicular node with normalization of all tumor markers. Etoposide 93-102 vasoactive intestinal peptide Homo sapiens 50-53 11043829-1 2000 Intermediate high dose VIP (etoposide, ifosfamide, cisplatin) achieved comparable efficacy and improved tolerance in comparison with high-dose chemotherapy plus PBSC in poor risk germ cell tumors. Etoposide 28-37 vasoactive intestinal peptide Homo sapiens 23-26 10637744-4 1999 BEP regimen (bleomycin, etoposide and cisplatin) salvaged with VIP (etoposide, ifosfamide and cisplatin) would be the standard therapy for advanced germ cell tumors since high-dose chemotherapy had no advantage on survival over the standard-dose regimen. Etoposide 68-77 vasoactive intestinal peptide Homo sapiens 63-66 9925076-1 1999 OBJECTIVE: To determine the applicability and safety of an ifosfamide, cisplatin, and etoposide (VIP) regimen as a neoadjuvant chemotherapy to a concomitant thoracic radiotherapy and cisplatin continuous infusion in locally advanced non-small cell lung cancer (NSCLC). Etoposide 86-95 vasoactive intestinal peptide Homo sapiens 97-100 10217181-13 1999 The choice of either etoposide (VIP) or vinblastine (VeIP) can be predicated upon which of these two drugs was associated with best results during premobilization chemotherapy. Etoposide 21-30 vasoactive intestinal peptide Homo sapiens 32-35 9821708-5 1998 However, this regimen was only partially effective to the patient with the pure hepatoid histological subtype, and an etoposide with ifosfamide and cisplatin (VIP) regimen as a salvage chemotherapy combined with complete tumor resection was useful to achieve complete remission (CR). Etoposide 118-127 vasoactive intestinal peptide Homo sapiens 159-162 9632268-0 1998 VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin"s disease. Etoposide 5-14 vasoactive intestinal peptide Homo sapiens 0-3 9552027-1 1998 PURPOSE: To compare standard therapy with bleomycin, etoposide, and cisplatin (BEP) to experimental therapy with etoposide, ifosfamide, and cisplatin (VIP) as primary treatment of men with advanced, disseminated germ cell tumors. Etoposide 113-122 vasoactive intestinal peptide Homo sapiens 151-154 7610394-3 1995 This regimen (VIP), however, has shown promise when used with high-dose carboplatin/etoposide as salvage therapy in patients with germ cell tumors not responding to first-line BEP. Etoposide 84-93 vasoactive intestinal peptide Homo sapiens 14-17 9535210-5 1998 In addition, preliminary results of a Hoosier Oncology Group phase II study of cisplatin/ifosfamide/etoposide (VIP) in combination with thoracic radiotherapy in patients with limited disease indicate that VIP has an acceptable toxicity profile and should be studied further. Etoposide 100-109 vasoactive intestinal peptide Homo sapiens 111-114 9535210-5 1998 In addition, preliminary results of a Hoosier Oncology Group phase II study of cisplatin/ifosfamide/etoposide (VIP) in combination with thoracic radiotherapy in patients with limited disease indicate that VIP has an acceptable toxicity profile and should be studied further. Etoposide 100-109 vasoactive intestinal peptide Homo sapiens 205-208 9158184-4 1997 Substituting taxol for etoposide in etoposide, ifosfamide and cisplatin (VIP), followed by high dose, is one possibility. Etoposide 23-32 vasoactive intestinal peptide Homo sapiens 73-76 9158184-4 1997 Substituting taxol for etoposide in etoposide, ifosfamide and cisplatin (VIP), followed by high dose, is one possibility. Etoposide 36-45 vasoactive intestinal peptide Homo sapiens 73-76 9181898-1 1997 For blood progenitor cell (BPC) mobilization, standard-dose VIP chemotherapy consisting of etoposide, ifosfamide and cisplatin has previously shown effective tumor reduction in solid tumor patients and sufficient progenitor cell mobilization for autologous blood cell transplantation. Etoposide 91-100 vasoactive intestinal peptide Homo sapiens 60-63 8839908-3 1996 The purpose of this study was to investigate the possibility of increased responses and survival with use of the combination of cisplatin, ifosfamide, etoposide (VIP-16) in comparison to the combination of cisplatin, ifosfamide, vinblastine (VIP) in non-operable NSCLC. Etoposide 151-160 vasoactive intestinal peptide Homo sapiens 162-165 8839908-3 1996 The purpose of this study was to investigate the possibility of increased responses and survival with use of the combination of cisplatin, ifosfamide, etoposide (VIP-16) in comparison to the combination of cisplatin, ifosfamide, vinblastine (VIP) in non-operable NSCLC. Etoposide 151-160 vasoactive intestinal peptide Homo sapiens 242-245 8677443-2 1996 Etoposide/ifosfamide/cisplatin (VIP) has produced overall response rates of 74% to 100% with complete response rates of 27% to 64% in SCLC patients. Etoposide 0-9 vasoactive intestinal peptide Homo sapiens 32-35 8711501-7 1996 Presently, this group is evaluating the role of chronic oral etoposide as maintenance chemotherapy for patients with extensive SCLC that responds to initial VIP treatment. Etoposide 61-70 vasoactive intestinal peptide Homo sapiens 157-160 7799046-1 1995 PURPOSE: Ifosfamide-containing therapy with cisplatin plus either etoposide (VIP) or vinblastine (VeIP) can cure of patients with relapsed germ cell tumors (GCTs), but results in substantial myelotoxicity. Etoposide 66-75 vasoactive intestinal peptide Homo sapiens 77-80 7690864-3 1993 In the 1989 study, vinblastine was replaced by etoposide, resulting in a chemotherapeutic regimen of 3 to 4 courses BEP and 3 to 4 courses VIP in patients with stage I to IV. Etoposide 47-56 vasoactive intestinal peptide Homo sapiens 139-142 7535146-2 1994 The combination of a standard-dose chemotherapy [VIP: VP16 (etoposide), ifosfamide, cisplatin] in combination with hematopoietic growth factors was shown to provide effective anti-cancer activity as well as to enable sufficient stem cell mobilization for clinical use. Etoposide 54-58 vasoactive intestinal peptide Homo sapiens 49-52 7535146-2 1994 The combination of a standard-dose chemotherapy [VIP: VP16 (etoposide), ifosfamide, cisplatin] in combination with hematopoietic growth factors was shown to provide effective anti-cancer activity as well as to enable sufficient stem cell mobilization for clinical use. Etoposide 60-69 vasoactive intestinal peptide Homo sapiens 49-52 8281497-6 1993 The patient was successfully treated with VIP regimen (etoposide, ifosfamide and cisplatin) followed by local irradiation. Etoposide 55-64 vasoactive intestinal peptide Homo sapiens 42-45 8386655-5 1993 The standard drug treatment worldwide for testicular cancer is PEB (cisplatin, etoposide, bleomycin) x3 for good risk and x4 for high risk patients, but there is cumulating evidence that VIP (cisplatin, ifosfamide, etoposide) is more effective for poor risk patients. Etoposide 79-88 vasoactive intestinal peptide Homo sapiens 187-190 8386655-5 1993 The standard drug treatment worldwide for testicular cancer is PEB (cisplatin, etoposide, bleomycin) x3 for good risk and x4 for high risk patients, but there is cumulating evidence that VIP (cisplatin, ifosfamide, etoposide) is more effective for poor risk patients. Etoposide 215-224 vasoactive intestinal peptide Homo sapiens 187-190 2174300-1 1990 A prospective study of four cycles of etoposide with ifosfamide and cisplatin (VIP) chemotherapy was conducted in 42 germ cell tumor (GCT) patients who were refractory to cisplatin with etoposide/vinblastine-based therapy. Etoposide 38-47 vasoactive intestinal peptide Homo sapiens 79-82 32636079-1 2021 BACKGROUND: Second-line salvage therapy for patients with metastatic germ-cell cancer (GCC) after the first-line combination of VIP (etoposide, ifosfamide, cisplatin) therapy has not been established. Etoposide 133-142 vasoactive intestinal peptide Homo sapiens 128-131 33284891-12 2020 As of September 12, 2020, the patient has undergone four cycles of VIP (etoposide, ifosfamide, cisplatin) chemotherapy after relapse, and the patient"s condition is currently in partial remission. Etoposide 72-81 vasoactive intestinal peptide Homo sapiens 67-70 31917123-6 2020 We administered VIP (etoposide, ifosfamide, cisplatin) chemotherapy for a recurrent liver tumor, and obtained complete pathological remission. Etoposide 21-30 vasoactive intestinal peptide Homo sapiens 16-19 30995853-8 2019 Second-line treatment with VIP (etoposide, ifosfamide, cisplatin) did not reverse the progression and the patient was consulted at our institute. Etoposide 32-41 vasoactive intestinal peptide Homo sapiens 27-30 28121937-0 2017 VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma. Etoposide 5-14 vasoactive intestinal peptide Homo sapiens 0-3 28121937-1 2017 We retrospectively reviewed outcomes of treatment with VIP (combination of etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma (STS).We analyzed the medical records of patients with advanced or relapsed STS who had undergone VIP treatment as second-line or more chemotherapy between January 2000 and December 2015. Etoposide 75-84 vasoactive intestinal peptide Homo sapiens 55-58 27284433-6 2016 The patient was treated with chemotherapy with the VIP protocol (cisplatin, etoposide and ifosfamide). Etoposide 76-85 vasoactive intestinal peptide Homo sapiens 51-54